Syndax Pharmaceuticals Inc Forecast, price target & analysts
Syndax Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Syndax Pharmaceuticals Inc Classifications & Recommendation:
Syndax Pharmaceuticals Inc Price Target
| Target Price | $36.86 |
| Price | $15.28 |
| Potential |
141.21%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Syndax Pharmaceuticals Inc 2026 .
The average Syndax Pharmaceuticals Inc target price is $36.86.
This is
141.21%
register free of charge
$51.00
233.77%
register free of charge
$16.00
4.71%
register free of charge
|
|
| A rating was issued by 15 analysts: 14 Analysts recommend Syndax Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Syndax Pharmaceuticals Inc stock has an average upside potential 2026 of
141.21%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 48.27 |
12 Analysts have issued a sales forecast Syndax Pharmaceuticals Inc 2024 . The average Syndax Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Syndax Pharmaceuticals Inc EBITDA forecast 2024. The average Syndax Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
12 Syndax Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Syndax Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.98 | -3.48 |
| 21.14% | 16.78% | |
| P/E | negative | |
| EV/Sales | 18.97 |
12 Analysts have issued a Syndax Pharmaceuticals Inc forecast for earnings per share. The average Syndax Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Syndax Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Syndax Pharmaceuticals Inc...
Current Syndax Pharmaceuticals Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Scotiabank | Locked ➜ Locked | Locked | Jan 08 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 10 2024 |
| JP Morgan | Locked ➜ Locked | Locked | Nov 21 2024 |
| Citigroup | Locked ➜ Locked | Locked | Nov 19 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 18 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 12 2024 |
| Goldman Sachs | Locked ➜ Locked | Locked | Nov 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Scotiabank: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 10 2024 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Nov 21 2024 |
|
Locked
Citigroup: Locked ➜ Locked
|
Nov 19 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 12 2024 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Nov 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
